Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections

Sotrovimab, an antibody active against severe acute respiratory syndrome coronavirus 2 that neutralizes antibodies, reduced the risk of COVID-19-related hospitalization or death in studies conducted before the emergence of the Omicron variant. The objective of this study is to evaluate the clinical...

Full description

Bibliographic Details

Published in:	Viruses
Main Authors:	Naoyuki Miyashita, Yasushi Nakamori, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Yoshihisa Ishiura, Tomoki Ito
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Subjects:	sotrovimab monoclonal antibody COVID-19 Omicron variant SARS-CoV-2
Online Access:	https://www.mdpi.com/1999-4915/15/6/1300